Connect with us

Artificial Intelligence

Patriot One Selected for $4.5M CAD Co-Investment from Digital Technology Supercluster COVID-19 Program

GlobeNewswire

Published

on

TORONTO, May 21, 2020 (GLOBE NEWSWIRE) — Patriot One Technologies Inc. (TSX: PAT) (OTCQX: PTOTF) (FRANKFURT: 0PL) (“Patriot One” or the “Company”), is pleased to announce it has been selected by Canada’s Digital Technology Supercluster (the “Supercluster”) for participation in a funding program for up to $4.5 million (CAD) in co-investment capital (the “Investment”) for the PATSCAN Multi-Sensor Threat Detection Platform (the “PATSCAN Platform”). This investment is proposed to fund the advanced development and deployment of the PATSCAN VRS health and safety detection modules for thermal elevated body temperature, facial mask screening, social distancing and contact tracing (the “Health & Safety Modules”) as part of the Company’s suite of video object recognition solutions.
The co-investment is subject to the completion of a definitive contract, which proposes to release funding under a two-stage approach to develop and deploy (a) a thermal screening module that highlights persons presenting with elevated temperatures in real-time, using commodity-priced thermal cameras, (b) additional computer modules that detect the presence or non-presence of medical and non-medical masks and face coverings, and the ability to highlight persons and problem areas where social distance requirements are not being maintained, and (c) cross-location monitoring and prediction of future outbreaks based on the overall trending of a combination of quantifiable indicators. Stage one is proposed to comprise up to $2.25 Million in Investment funding to demonstrate the development and deployment of Modules over a four to six-month timeframe on-site with five or more co-development customers, and commercial validation by one or more customers recruited as a co-development partner for Stage two. Following a successful Stage One deployment, the Company will receive a second Investment advance of up to $2.25 Million over a six to eight-month timeframe to refine the Health & Safety Modules and redeploy same with Stage One partners and customer(s). Expenses eligible for Investment are subject to the Supercluster’s COVID-19 Program Co-Investment Guidelines.The Health & Safety Modules are additional video object recognition solutions that have been added to the PATSCAN Platform, which also includes weapon detection, disturbance and fight detection modules.“Our mission has always been to create safer communities by detecting dangers before they become a threat to our global citizens and communities,” shared Martin Cronin, CEO of Patriot One. “We believe our thermal camera solution will greatly help businesses, healthcare, retail, sport, entertainment, and hospitality industries as they re-open the economy. The thermal and facial mask screening solutions will allow property management to screen employees and customers for elevated body temperatures, and if detected, those individuals can proceed through secondary screening process for further evaluation, as well as for compliance with mask protocols.”“The Health & Safety Modules can use off-the-shelf thermal cameras, powered with our PATSCAN artificial intelligence (AI) software, to identify and analyze instances of elevated body temperature,” explained Dietmar Wennemer, Patriot One’s new President and COO. “It is not as simple as installing a thermal camera and expecting to get a precise temperature reading; the fine temperature tolerances are not detected with every standard IR thermal camera. The key is in our use of machine learning to identify anomalies. Any anomalous detection outside a nominal body temperature range will result in an immediate alert, which will be instantly transmitted to onsite security for further action. This new thermal module is compatible with the PATSCAN Platform and compatible with all other solutions including the facial mask detection module. All detection Modules can be monitored remotely. We also have two excellent AI research teams that continuously enhance our AI features and the effectiveness of the computer neural networks we utilize for our advanced solutions.”“We are proud to support the development and deployment of the PATSCAN Platform to improve the health and safety of all Canadians through the Health & Safety modules being developed by Patriot One,” said Sue Paish, CEO of the Digital Technology Supercluster. “This innovative screening technology will support Canada in safely re-opening the economy in the COVID 19 environment.”Development of the PATSCAN Platform’s VRS thermal elevated body temperature and facial mask detection modules has already begun, with testing in four (4) distinct North American settings, including a hospital, business office, sport stadium and law enforcement facility. Following these onsite client tests and evaluations, Patriot One and the Digital Technology Supercluster will discuss the commercial rollout and deployment of these new Health & Safety Modules across Canada, as part of the overall PATSCAN Multi-Sensor Covert Threat Detection Platform.In addition, the Company has plans to undertake a corporate awareness campaign to raise its profile in the U.S. domestic investment community, and has engaged Winning Media, LLC (“Winning Media”) to provide Patriot One with a breadth of targeted digital media and corporate brand recognition initiatives. Winning Media is a Houston, Texas – based marketing agency that specializes in digital and corporate brand marketing services to enhance corporate visibility and retail investor awareness. The agency will handle specific functions of digital distribution of public information relating to the Company. Winning Media and its principals do not have any direct or indirect equity interest in the Company and will not receive any securities of the Company as compensation for their services.Respectfully“Martin Cronin”Martin Cronin, CEOAbout Patriot One Technologies Inc.
Patriot Ones’ mission is to deliver innovative threat detection and counter-terrorism solutions for safer communities. Our PATSCAN™ Multi-Sensor Covert Threat Detection Platform provides a network of advanced sensor technologies with powerful next generation AI/machine learning software. The network can be covertly deployed from far perimeter to interiors across multiple weapons-restricted facilities. The PATSCAN™ platform identifies and reports threats wherever required; car park, building approach, employee and public entryways and inside the facilities. Each solution in the platform identifies weapons, related threats or disturbances for immediate security response. Our motto Deter, Detect and Defend is based on the belief that widespread use of the PATSCAN™ platform will act as an effective deterrent to diminish the epidemic of active threats around the globe. For more information, visit: www.patriot1tech.com or follow us on Twitter and Facebook.
About Digital Technology Supercluster:The Digital Technology Supercluster is led by global companies such as MDAMicrosoftTelusTeck Resources Limited, Mosaic Forest ManagementLululemonLifeLabs and Terramera, and tech industry leaders such as 1QbitD-Wave Systems, Finger Food Advanced Technology Group, Sanctuary AI, and LlamaZOO. Members also include BC’s post-secondary institutions such as Emily Carr University of Art + DesignBritish Columbia Institute of TechnologyUniversity of British Columbia and Simon Fraser University. A full list of Members can be found here.About the COVID-19 Program:
The COVID-19 Program funds projects that contribute to improving the health and safety of Canadians, supporting Canada’s ability to address issues created by the COVID-19 outbreak. In addition, these projects will build expertise and capacity to address and anticipate issues that may arise in future health crises. More information can be found here.
For further information, please contact:Patriot One Inquiries
info@patriot1tech.com
www.patriot1tech.com
Investor Relations
John Martin, Patriot One
+1 (888) 728-1332
johnm@patriot1tech.com
Media Contacts:
Scott Ledingham, Patriot One
+1-613-806-7135
scott@prmedianow.com
Digital Technology Supercluster
Elysa Darling
elysa@switchboardpr.com
587-890-9833
CAUTIONARY DISCLAIMER STATEMENT:
No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to system sales, product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects”, “believes”, and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include counterparty default and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements only as expressly required by applicable law.
Neither the Toronto Stock Exchange (TSX) nor its Regulation Services Provider (as that term is defined in policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Tempus Launches COVID-19-Specific Clinical and Research Initiatives for Oncology

GlobeNewswire

Published

on

CHICAGO, May 30, 2020 (GLOBE NEWSWIRE) — Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, introduced a series of offerings designed to both advance vital research and support physicians in treating cancer patients, despite the challenges of the COVID-19 pandemic. Tempus is equipping physicians with the tools they need to treat high-risk patients while limiting their exposure to the virus, with mobile phlebotomy services, on-demand virtual case reviews, and COVID-19 PCR diagnostic testing for cancer patients.
“Cancer continues to be among the leading causes of death worldwide, and now more than ever, it is critical that cancer patients continue to receive the care and treatment they need for survival despite the pandemic,” said Eric Lefkofsky, Founder and CEO. “In the last few months, we’ve quickly mobilized to create offerings that ease the burden on physicians treating cancer patients amidst the threat of COVID-19, through a series of services and tests that are badly needed to ensure therapies aren’t disrupted.”COVID-19 PCR Diagnostic Testing
Earlier this month, Tempus launched a diagnostic polymerase chain reaction (PCR) test for COVID-19. Tempus’ CAP-accredited/CLIA-certified labs in Chicago and Atlanta are supporting the acceleration of testing in the U.S., and expect to test approximately 12,000 patients daily across both labs, with the ability to scale further if needed. Tempus makes it seamless for physicians to test their patients for the virus, providing results within 24-48 hours at no cost to the patient as Tempus bills insurance directly.  
Mobile Phlebotomy
Tempus now offers mobile phlebotomy services, which are available to patients who require a blood draw but are too sick or unable to travel to the clinic, or do not have access to an in-office phlebotomist or draw site. Experts are able to perform blood draws in patients’ homes for any Tempus test in which a blood sample is required, at no added cost.
Virtual Case Reviews
Tempus’ on-demand virtual case review system provides clinical support to physicians and care teams in a timely manner when an in-person meeting isn’t possible. Tempus’ Medical Affairs team is available to answer patient report questions in real-time in a secure portal.   In addition, Tempus now offers a variety of tele-health support services specific to COVID-19 if needed.
Research Collaboration
Tempus has launched a large research collaboration to structure data for up to 50,000 COVID-19 positive patients.  As part of the IRB approved study, Tempus is partnering with providers to collect data on COVID-19 patients, which Tempus is structuring and de-identifying without cost.  In addition, Tempus expects to perform full transcriptomic profiling of approximately 10,000 patients within the cohort. All data will be shared with all participating institutions without restriction. 
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Erin Carron
communications@tempus.com

Continue Reading

Artificial Intelligence

Tempus’ TIME Trial™ Program Reaches Critical Scale and Operational Milestones

GlobeNewswire

Published

on

CHICAGO, May 29, 2020 (GLOBE NEWSWIRE) — Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, has reached a milestone in fully enrolling 2,500 oncologists into its Tempus Integrated Molecular Evaluation (TIME) Trial™ Program that seeks to rapidly match patients largely in the community setting to targeted clinical trials. To date, Tempus has signed up over 50 provider networks, over 30 unique biomarker trials, and has rapidly opened sites onto trials in an average of 10 days. Through the TIME Trial™ Program, Tempus is bringing the very best clinical trials to communities across the country, giving thousands of patients access to novel therapeutics.
“We have experience with clinical trial rapid deployment models, however Tempus provides an unparalleled level of commitment and support in aligning all involved parties and streamlining the process, especially given the challenges of the COVID-19 pandemic,” said Dr. Julio Peguero, Director of Research of Oncology Consultants. “We ultimately met our target goal of activating this trial in just two weeks, and hope to do the same for future patients.”Last spring, Tempus launched the TIME Trial™ Program in an effort to increase clinical trial participation by using real-time clinical and molecular data to match patients to trials, and then rapidly open pre-qualified sites once a patient has been identified. Since then, Tempus has built its TIME Trial™ Network, inclusive of some of the country’s top community hospitals and academic medical centers, totaling over 50 research sites and 2,500 oncologists.As of today, the program has 30 pharma-sponsored clinical trials, covering dozens of unique, actionable biomarkers across both solid and hematological malignancies. Every week, Tempus screens thousands of new patients against the criteria of the ultra-rare trials in the TIME Trial™ Network. Thus far, Tempus has matched nearly 1,000 patients to the trials in its portfolio and averaged just under 10 days from patient screened to site activated.“Cutting-edge cancer therapies increasingly target narrower populations of patients, and the clinical trials that study these therapies require equally specific patient populations,” said Amy Franzen, Vice President of Operations and Program Lead. “Tempus is able to use its advanced technology, access to real-time data, and strong operations to get the right patients access to the right therapies, closer to home.”Tempus screens patients from sites in the TIME Trial™ Network against applicable inclusion/exclusion criteria utilizing genomic sequencing data, matched with the patients’ clinical data. Then, Tempus applies its computational algorithm to provide rapid, comprehensive matches to applicable trials that can be brought to the patient. Once a patient has been screened and matched, Tempus provides the patient’s physician with a report that ranks relevant trials. If the physician expresses interest in enrolling his or her patient in a trial, the Site and Sponsor leverage a standard contract, standard rate card, and a central IRB to rapidly open the clinical trial and enroll the patient into the study in under two weeks.For the same reason that precision medicine is now possible due to technological advances such as cost effective genomic sequencing at scale, the maturing of artificial intelligence, and the evolution of cloud technology, it is now possible to run clinical trials more efficiently and based on real-time data. Tempus is increasing the speed of clinical trials and reaching into community settings, where the majority of cancer patients are treated today.About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Erin Carron
communications@tempus.com

Continue Reading

Artificial Intelligence

Completely Online Summer Math Camps Offered to Meet Strong Demand from Parents During COVID-19

GlobeNewswire

Published

on

San Diego, May 29, 2020 (GLOBE NEWSWIRE) — Parents looking for a summer camp this year may find that there are limited options due to COVID-19 social distancing guidelines. Art of Problem Solving (AoPS), a leader in math education that has prepared hundreds of thousands of students for some of the most prestigious universities, has transformed its Summer Camp activities online to create a collaborative learning and social space for children in third grade through high school. The Summer Camp activities help students develop problem solving skills through group activities in math and related subjects.Though this is the fourth year that Art of Problem Solving has offered a Summer Camp, this is the first time the organization is offering the camp experience completely online. Activities include learning how to develop cryptographic skills to protect internet security, to a class that integrates math learning as part of a poetry project that concludes with a Poetry Slam. The two-week and four-week sessions start in June and last through the summer.“As a result of the COVID-19 pandemic, many parents are seeking a summer camp experience for their children that conforms to social distancing norms while encouraging learning and collaboration,” said Richard Rusczyk, the founder of Art of Problem Solving, which has offered classes since 2003. “At Art of Problem Solving, we quickly adapted our on-campus Summer Camp experience with our online academic models. Our first-ever online Summer Camp is designed to encourage students to develop problem solving skills in a personalized and collaborative group environment.”The COVID-19 pandemic has created wider public awareness of the relevancy of math and statistics in everyday life. Rusczyk said his organization has seen that interest reflected in demand from more parents and children who see math skills as increasingly important. Also, in response to COVID-19, the company offered for a limited time a free trial to its Beast Academy program that integrates comic-style “beast” characters and exercises, puzzles and games.The Art of Problem Solving began in 1993 with a pair of textbooks for middle and high school math contest participants. Ten years later, Art of Problem Solving launched a website with an online school and full math curriculum designed for high-performing math learners. Every member of the 2015, 2016, 2018, and 2019 U.S. International Math Olympiad teams―each of which took first place in the competition―are Art of Problem Solving alumni who collectively participated in more than 110 Art of Problem Solving Online courses. The Art of Problem Solving is an ACS WASC Accredited School that offers programs online and, prior to COVID-19, at its nationwide campus locations. The organization also works with school districts to integrate their offerings as part of school math lessons.Looking beyond the immediate pandemic, problem solving skills are considered to be essential to the nation’s future workforce. As professions shift toward greater use of automation and artificial intelligence, there is expected to be an increased demand for people who have the ability to identify creative solutions and manage these developments. Critical thinking and problem solving is a top skill identified by National Association of Colleges and Employers.About Art of Problem SolvingArt of Problem Solving has successfully trained hundreds of thousands of motivated students in preparation for success at top-tier colleges and careers. Through rigorous, high-quality K-12 math curriculum, online classes and learning centers, Art of Problem Solving trains today’s brightest minds to solve tomorrow’s challenges. For additional information, visit www.artofproblemsolving.com.Jaclyn Walian
MIG
jwalian@migcom.com

Continue Reading

Trending

Roboticulized is part of PICANTE Media and Events, a leading media and boutique event organizer in the European Union with a monthly reach of +50,000 readers. The official company (PROSHIRT SRL), has been listed for 4 years in a row among the top 3 Advertising and market research agencies in the local Top Business Romania Microcompanies based on the Financial Reports. Roboticulized digests / hand picks the latest news about the AI industry and serves them to you daily.

Contact us: sales@picante.today

Editorial / PR Submissions

© Roboticulized.com 2019 - 2020 - part of PICANTE Media. All rights reserved. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania